RTP Mobile Logo
Select Publications

Caron Jacobson, MD

Fowler NH et al. Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: Interim analysis of the phase 2 Elara trial. ASH 2020;Abstract 1149.

Jacobson CA et al. Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24). ASCO 2021;Abstract 7515.

Palomba ML et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in Transcend NHL 001. ASH 2020;Abstract 118.

Siddiqi S et al. Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of Transcend CLL 004, including high-risk and ibrutinib-treated patients. ASH 2020;Abstract 546.

Wang M et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382(14):1331-42. Abstract

David G Maloney, MD, PhD

Jacobson CA et al. Axicabtagene ciloleucel in the non-trial setting: Outcomes and correlates of response, resistance, and toxicity. J Clin Oncol 2020;38(27):3095-106. Abstract

Nastoupil LJ et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium. J Clin Oncol 2020;38(27):3119-28. Abstract

Pinnix CC et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 2020;4(13):2871-83. Abstract

Sterner RC et al. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J 2021;11(4):69. Abstract

Nikhil C Munshi, MD

Agha ME et al. CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. ASCO 2021;Abstract 8013.

Munshi NC et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384(8):705-16. Abstract

Raje N et al. Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: Analyses of high-risk subgroups in the KarMMa study. ASH 2020;Abstract 3234.

Samur MK et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nature Comm 2021;12(1):868. Abstract